Clinical studies have indicated that a combination of anti‐EGFR targeted therapy and KRAS c.34G>T (p.G12C) inhibitor could be an effective treatment strategy in KRAS c.34G>T (p.G12C)‐mutated colorectal cancer.13, 14. The gene discussed is EGFR; the disease is colorectal cancer.